AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27022961 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training (CCT)
Number of subjects: 119
Study 27022961 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 119
Study 27287454 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation during DMSA scan
Number of subjects: 798
Study 27287454 — intervention group
Group type: COMPARATOR
Intervention: Non-sedation during DMSA scan
Number of subjects: 798
Study 27287454 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective sedation during DMSA scan
Number of subjects: 798
Study 25390874 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia (ZrO₂) abutments
Number of subjects: 20
Study 25390874 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium (Ti) abutments
Number of subjects: 20
Study 22392358 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic surgery (SILS)
Number of subjects: 40
Study 22392358 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic adrenalectomy
Number of subjects: 40
Study 19224163 — intervention group
Group type: EXPERIMENTAL
Intervention: Anluohuaxian tablet + gamma-IFN
Number of subjects: 60
Study 19224163 — intervention group
Group type: COMPARATOR
Intervention: Anluohuaxian tablet
Number of subjects: 60
Study 19224163 — intervention group
Group type: COMPARATOR
Intervention: gamma-IFN
Number of subjects: 60
Study 19224163 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (anluohuaxian tablet + gamma-IFN)
Number of subjects: 60
Study 17966930 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cytopathology of oral brush biopsies
Number of subjects: 0
Study 17966930 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA image cytometry as an adjuvant diagnostic tool
Number of subjects: 0
Study 14687313 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials mailed to intervention practice households; waiting and examination room posters provided to intervention office practices.
Number of subjects: 4270
Study 14687313 — intervention group
Group type: COMPARATOR
Intervention: Control practices (51 practices) without the educational intervention.
Number of subjects: 4270
Study 11726432 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin B complex (folate 2.5 mg, B(6) 25 mg, and B(12) 500 microg) daily for 1 week before surgery
Number of subjects: 53
Study 11726432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 9656906 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine + simulated dry needling
Number of subjects: 30
Study 9656906 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling + simulated local anesthetic
Number of subjects: 30
Study 9656906 — intervention group
Group type: COMPARATOR
Intervention: Simulated local anesthetic + simulated dry needling
Number of subjects: 30
Study 9656906 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 30
Study 8485020 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg MTX i.v.
Number of subjects: 9
Study 8485020 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg MTX i.m.
Number of subjects: 9
Study 8485020 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg MTX p.o.
Number of subjects: 9
Study 8485020 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg MTX (all routes)
Number of subjects: 9
Study 3318348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 2 mg/day for 7 days
Number of subjects: 23
Study 3318348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31273290 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + D (Docetaxel)
Number of subjects: 0
Study 31273290 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + AA (Abiraterone Acetate)
Number of subjects: 0
Study 31273290 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose AA (250 mg)
Number of subjects: 0
Study 31273290 — intervention group
Group type: COMPARATOR
Intervention: ADT + AA
Number of subjects: 0
Study 30264056 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of amino acid and sodium hyaluronate gel
Number of subjects: 136
Study 30264056 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline solution (Control)
Number of subjects: 136
Study 27003242 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training (12-form Yang style Tai Chi)
Number of subjects: 31
Study 27003242 — intervention group
Group type: COMPARATOR
Intervention: Control group (general interest classes)
Number of subjects: 31
Study 26866082 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 20 mcg 2-hourly up to a maximum of 4 doses
Number of subjects: 83
Study 26866082 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin according to WHO protocol
Number of subjects: 83
Study 22248659 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine (500 or 1000 mg, twice daily) plus danoprevir (100 or 200 mg, every 8 hours, or 600 or 900 mg, twice daily)
Number of subjects: 87
Study 22248659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 19744259 — intervention group
Group type: COMPARATOR
Intervention: Intralesional sodium stibogluconate (SSG) alone
Number of subjects: 30
Study 19744259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional SSG + intramuscular SSG
Number of subjects: 30
Study 19744259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional SSG + oral ketoconazole
Number of subjects: 30
Study 18503923 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) - single 5‐minute ischemia/reperfusion interval before coronary occlusion (n = 9)
Number of subjects: 25
Study 18503923 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane anesthesia - 1.6% enflurane 15 minutes before and during graft attachment (n = 8)
Number of subjects: 25
Study 18503923 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 25
Study 15713352 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose (0.4-0.6 mg/day)
Number of subjects: 101
Study 15713352 — intervention group
Group type: COMPARATOR
Intervention: Control (no voglibose)
Number of subjects: 101
Study 15713352 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 101
Study 12815682 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sclerosis patients
Number of subjects: 27
Study 12815682 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 12798444 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (80 mg slow release matrix tablet, acute application)
Number of subjects: 0
Study 12798444 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (2-month medication regimen)
Number of subjects: 0
Study 12798444 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (after nanoplaque generation)
Number of subjects: 0
Study 12798444 — intervention group
Group type: COMPARATOR
Intervention: HDL (as a comparison)
Number of subjects: 0
Study 9583763 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised fitness programme
Number of subjects: 81
Study 9583763 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 7634730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone injection with lidocaine
Number of subjects: 109
Study 7634730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone injection with bupivacaine
Number of subjects: 109
Study 7634730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone injection (regardless of anesthetic)
Number of subjects: 109
Study 2677289 — intervention group
Group type: EXPERIMENTAL
Intervention: Vialon I.V. catheters
Number of subjects: 191
Study 2677289 — intervention group
Group type: COMPARATOR
Intervention: Teflon I.V. catheters
Number of subjects: 191
Study 411398 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized atropine sulphate (1 mg)
Number of subjects: 15
Study 411398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 411398 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine alone
Number of subjects: 15
Study 411398 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (20 mg)
Number of subjects: 15
Study 411398 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (0.625 mg)
Number of subjects: 15
Study 411398 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol plus atropine
Number of subjects: 15
Study 411398 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol or atropine pre-treatment
Number of subjects: 15
Study 31585191 — intervention group
Group type: EXPERIMENTAL
Intervention: SA3Ag vaccine (low-dose: 102; mid-dose: 101; high-dose: 101)
Number of subjects: 404
Study 31585191 — intervention group
Group type: COMPARATOR
Intervention: Placebo (102 initial; 181 booster)
Number of subjects: 404
Study 31585191 — intervention group
Group type: EXPERIMENTAL
Intervention: SA3Ag vaccine (all doses)
Number of subjects: 404
Study 31585191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 31585191 — intervention group
Group type: EXPERIMENTAL
Intervention: SA3Ag vaccine (mid-dose and high-dose)
Number of subjects: 404
Study 31585191 — intervention group
Group type: EXPERIMENTAL
Intervention: SA3Ag vaccine (low-dose and placebo)
Number of subjects: 404
Study 28842581 — intervention group
Group type: EXPERIMENTAL
Intervention: C34-PEG4-Chol (10 mg, 10 mg, and 20 mg)
Number of subjects: 5
Study 28842581 — intervention group
Group type: EXPERIMENTAL
Intervention: C34-PEG4-Chol (10 mg, 20 mg)
Number of subjects: 5
Study 28842581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 25757714 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted CBT for psychosis (CaCBTp) plus treatment as usual (TAU)
Number of subjects: 116
Study 25757714 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 116
Study 22874661 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (3 weekly sessions for 12 weeks)
Number of subjects: 36
Study 22874661 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behaviour Therapy (1 weekly session for 12 weeks)
Number of subjects: 36
Study 21461372 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0
Study 21461372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 0
Study 21461372 — intervention group
Group type: COMPARATOR
Intervention: Control (standard supportive care)
Number of subjects: 0
Study 19788025 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine, 5 mg daily for 15 days
Number of subjects: 233
Study 19788025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 17390549 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 10 mg
Number of subjects: 35
Study 17390549 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 35
Study 17390549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 14967267 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐piece AcrySof IOLs (AcrySof SA30 or SA60)
Number of subjects: 52
Study 14967267 — intervention group
Group type: COMPARATOR
Intervention: Multipiece AcrySof IOLs (AcrySof MA30 or MA60)
Number of subjects: 52
Study 14967267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOL types
Number of subjects: 52
Study 11676093 — intervention group
Group type: EXPERIMENTAL
Intervention: Handbills as a medium for public relations for the Nutrition Seminar.
Number of subjects: 0
Study 11676093 — intervention group
Group type: EXPERIMENTAL
Intervention: Local voluntary organization route for distributing handbills.
Number of subjects: 0
Study 9360254 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg)
Number of subjects: 20
Study 9360254 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (400 mg)
Number of subjects: 20
Study 8508863 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg zofenopril once daily
Number of subjects: 21
Study 8508863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3327854 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 4
Study 3327854 — intervention group
Group type: EXPERIMENTAL
Intervention: Flordipine 25 mg
Number of subjects: 4
Study 3327854 — intervention group
Group type: EXPERIMENTAL
Intervention: Flordipine 50 mg
Number of subjects: 4
Study 3327854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31279794 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone
Number of subjects: 104
Study 31279794 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg yohimbine
Number of subjects: 104
Study 31279794 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hydrocortisone and 10 mg yohimbine combined
Number of subjects: 104
Study 31279794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 27785892 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant IL-2
Number of subjects: 312
Study 27785892 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 312
Study 27785892 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 312
Study 25956282 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive voice response phone call followed by a letter 1 week later if primary non-adherence continued
Number of subjects: 245
Study 25956282 — intervention group
Group type: COMPARATOR
Intervention: No outreach (control group)
Number of subjects: 245
Study 24020152 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual cue
Number of subjects: 69
Study 24020152 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory cue
Number of subjects: 69
Study 24020152 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined audio-visual cue
Number of subjects: 69
Study 24020152 — intervention group
Group type: COMPARATOR
Intervention: No cue
Number of subjects: 69
Study 24020152 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart grab bars with cues
Number of subjects: 69
Study 22123383 — intervention group
Group type: EXPERIMENTAL
Intervention: icatibant
Number of subjects: 88
Study 22123383 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 88
Study 19550428 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cups of decaffeinated Italian espresso coffee
Number of subjects: 15
Study 19550428 — intervention group
Group type: COMPARATOR
Intervention: One cup of decaffeinated Italian espresso coffee
Number of subjects: 15
Study 17362456 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine-soaked sponge (Group R, n = 32)
Number of subjects: 64
Study 17362456 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine-soaked sponge (Group L, n = 32)
Number of subjects: 64
Study 15465617 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose of pegylated interferon weekly alone
Number of subjects: 0
Study 15465617 — intervention group
Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 0
Study 11806858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (induced by reducing plasma tryptophan by 80%)
Number of subjects: 30
Study 11806858 — intervention group
Group type: COMPARATOR
Intervention: Control group (plasma tryptophan reduced by 16%)
Number of subjects: 30
Study 9495509 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1600 mg/day as the citrate)
Number of subjects: 236
Study 9495509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 7992293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20, 40 and 80 mg/day)
Number of subjects: 48
Study 7992293 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10, 20 and 40 mg/day)
Number of subjects: 48
Study 7992293 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin and Pravastatin
Number of subjects: 48
Study 2522392 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated/social interaction
Number of subjects: 56
Study 2522392 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated/child-directed
Number of subjects: 56
Study 2522392 — intervention group
Group type: EXPERIMENTAL
Intervention: Segregated/social interaction
Number of subjects: 56
Study 2522392 — intervention group
Group type: EXPERIMENTAL
Intervention: Segregated/child-directed
Number of subjects: 56
Study 1227823 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistidine hydrochloride, 4 mg three times daily
Number of subjects: 50
Study 1227823 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blind study with Betahistidine hydrochloride
Number of subjects: 50
Study 29894705 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 236
Study 29894705 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 236
Study 29894705 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tDCS and Escitalopram
Number of subjects: 236
Study 28700009 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 40
Study 28700009 — intervention group
Group type: COMPARATOR
Intervention: Single-port laparoscopic cholecystectomy
Number of subjects: 40
Study 25636234 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing fruit and vegetable advertisements (prime condition)
Number of subjects: 907
Study 25636234 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no advertisements)
Number of subjects: 907
Study 23174515 — intervention group
Group type: EXPERIMENTAL
Intervention: OPUS (intensive early-intervention programme)
Number of subjects: 0
Study 23174515 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 23174515 — intervention group
Group type: EXPERIMENTAL
Intervention: OPUS
Number of subjects: 0
Study 21714689 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative depression care intervention
Number of subjects: 249
Study 21714689 — intervention group
Group type: COMPARATOR
Intervention: Usual depression care
Number of subjects: 249
Study 18492265 — intervention group
Group type: EXPERIMENTAL
Intervention: NP 06‐1 (370 mg each, two capsules twice daily)
Number of subjects: 80
Study 18492265 — intervention group
Group type: EXPERIMENTAL
Intervention: NP 06‐1
Number of subjects: 80
Study 18492265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 16980638 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 270
Study 16980638 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity increase between 6 and 12 months
Number of subjects: 270
Study 14585550 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard opioid management plus Reiki (Arm B)
Number of subjects: 24
Study 14585550 — intervention group
Group type: COMPARATOR
Intervention: Standard opioid management plus rest (Arm A)
Number of subjects: 24
Study 11085972 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 0
Study 8614967 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU of rHuEPO per kg of body weight intravenously twice a week
Number of subjects: 30
Study 8614967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1393034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of up to 20 mg papaveretum
Number of subjects: 100
Study 1393034 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study 2862523 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 291
Study 2862523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 291
Study 2862523 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening-primrose oil
Number of subjects: 291
Study 2862523 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of lignocaine and hydrocortisone
Number of subjects: 291
Study 2862523 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestagens
Number of subjects: 291
Study 29679427 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-IOD
Number of subjects: 21
Study 29679427 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-IOD
Number of subjects: 21
Study 29433845 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-led HBA program for 6 months, followed by DVD-guided HBA for another 6 months
Number of subjects: 232
Study 29433845 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 232
Study 26963505 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring (25 mg), inserted 4-weekly for 12 weeks
Number of subjects: 280
Study 26963505 — intervention group
Group type: COMPARATOR
Intervention: Placebo ring, inserted 4-weekly for 12 weeks
Number of subjects: 280
Study 26963505 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring (25 mg)
Number of subjects: 280
Study 24507870 — intervention group
Group type: EXPERIMENTAL
Intervention: SMFV (white rice with protein-rich main dishes, fat-rich food item, and vegetables)
Number of subjects: 9
Study 24507870 — intervention group
Group type: EXPERIMENTAL
Intervention: SMF (white rice with protein-rich main dishes and fat-rich food item)
Number of subjects: 9
Study 24507870 — intervention group
Group type: EXPERIMENTAL
Intervention: SM (white rice with protein-rich main dishes)
Number of subjects: 9
Study 24507870 — intervention group
Group type: COMPARATOR
Intervention: S (white rice alone)
Number of subjects: 9
Study 23225837 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometholone combined with pranoprofen eye drops
Number of subjects: 27
Study 23225837 — intervention group
Group type: COMPARATOR
Intervention: Fluorometholone eye drops
Number of subjects: 27
Study 21029467 — intervention group
Group type: EXPERIMENTAL
Intervention: NEAT Girls intervention (12-month multi-component school-based intervention including enhanced school sport sessions, interactive seminars, nutrition workshops, lunch-time physical activity sessions, PA and nutrition handbooks, parent newsletters, pedometers for self-monitoring, text messaging for social support)
Number of subjects: 0
Study 21029467 — intervention group
Group type: EXPERIMENTAL
Intervention: NEAT Girls intervention
Number of subjects: 0
Study 16930863 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 106